EHA Library - The official digital education library of European Hematology Association (EHA)

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA:SINGLE CENTER EXPERIENCE
Author(s):
Selami Kocak Toprak
,
Selami Kocak Toprak
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Erden Atilla
,
Erden Atilla
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Pinar Ataca Atilla
,
Pinar Ataca Atilla
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Sinem Civriz Bozdag
,
Sinem Civriz Bozdag
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Meltem Kurt Yuksel
,
Meltem Kurt Yuksel
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Pervin Topcuoglu
,
Pervin Topcuoglu
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Taner Demirer
,
Taner Demirer
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Onder Arslan
,
Onder Arslan
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Muhit Ozcan
,
Muhit Ozcan
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Mutlu Arat
,
Mutlu Arat
Affiliations:
Florence Nightingale Hospital,Istanbul,Turkey
Osman Ilhan
,
Osman Ilhan
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Hamdi Akan
,
Hamdi Akan
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Meral Beksac
,
Meral Beksac
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Nahide Konuk
,
Nahide Konuk
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
Akin Uysal
,
Akin Uysal
Affiliations:
Koru Hospital,Ankara,Turkey
Gunhan Gurman
Gunhan Gurman
Affiliations:
Ankara University School of Medicine Department of Hematology,Ankara,Turkey
(Abstract release date: 05/18/17) EHA Library. Atilla E. 05/18/17; 182898; PB2185
Dr. Erden Atilla
Dr. Erden Atilla
Contributions
PDF Abstract
Abstract

Abstract: PB2185

Type: Publication Only

Background
Mantle cell lymphoma accounts for relatively small proportion (3%>10%) of non-Hodgkin lymphoma. High-dose chemotherapy (HDT) and autologous-stem cell transplantation (ASCT) has played a critical role in the treatment of mantle cell lymphoma. Regardless of that, mantle cell lymphoma remains largely a relapsing/remitting disease.

Aims

Our aim is to present our mantle cell lymphoma patients who underwent ASCT.

Methods
We retrospectively evaluated our 21 mantle cell NHL patients. The patients were followed after ASCT for relapse

Results

Patients were followed by a median time of 56.9 months (range, 6-170 months).The median age at diagnosis was 45 (range, 18-69), female to male ratio:5/16. The stages and MIPI scores at diagnosis were as follows: 5% stage II, 19% stage III, 76% stage IV; Low MIPI 29%, intermediate MIPI 48% and high MIPI 23%. First line treatments were R-CHOP for 6 cycles in 6 patients (29%) and R-CHOP for 3 cycles followed by R-DHAP in 15 patients (71%). The median time to ASCT was 20 months (range, 7-48 months). All patients were in at least partial remission at the time of ASCT. The transplant conditioning regimen was CVB in 5 patients (24%) and R+/-ICE in 5 patients (24%), R+/- BEAM in 11 patients (52%). Six patients (29%) achieved complete remission. Four patients (19%) died within three months of ASCT due to infection. Eleven patients (52%) was relapsed with a median time of 39 months (range, 4-123 months). Ten patients received BORID (bortezomib, rituximab, dexamethasone) and 1 patient received lenalidomide as salvage therapy and six of them achieved complete remission. Three patients underwent allogeneic hematopoietic stem cell transplantation as well as two patients received ibrutinib as fourth line therapy and followed in remission. The 3 year overall survival was 71%.

Conclusion
ASCT is a part of initial treatment strategy in fit patients with mantle cell lymphoma however %19 patients in our series had transplant related toxicity. Today, novel agents may present a less intensive approach for achieving response.

Session topic: 22. Stem cell transplantation - Clinical

Keyword(s): Mantle cell lymphoma

Abstract: PB2185

Type: Publication Only

Background
Mantle cell lymphoma accounts for relatively small proportion (3%>10%) of non-Hodgkin lymphoma. High-dose chemotherapy (HDT) and autologous-stem cell transplantation (ASCT) has played a critical role in the treatment of mantle cell lymphoma. Regardless of that, mantle cell lymphoma remains largely a relapsing/remitting disease.

Aims

Our aim is to present our mantle cell lymphoma patients who underwent ASCT.

Methods
We retrospectively evaluated our 21 mantle cell NHL patients. The patients were followed after ASCT for relapse

Results

Patients were followed by a median time of 56.9 months (range, 6-170 months).The median age at diagnosis was 45 (range, 18-69), female to male ratio:5/16. The stages and MIPI scores at diagnosis were as follows: 5% stage II, 19% stage III, 76% stage IV; Low MIPI 29%, intermediate MIPI 48% and high MIPI 23%. First line treatments were R-CHOP for 6 cycles in 6 patients (29%) and R-CHOP for 3 cycles followed by R-DHAP in 15 patients (71%). The median time to ASCT was 20 months (range, 7-48 months). All patients were in at least partial remission at the time of ASCT. The transplant conditioning regimen was CVB in 5 patients (24%) and R+/-ICE in 5 patients (24%), R+/- BEAM in 11 patients (52%). Six patients (29%) achieved complete remission. Four patients (19%) died within three months of ASCT due to infection. Eleven patients (52%) was relapsed with a median time of 39 months (range, 4-123 months). Ten patients received BORID (bortezomib, rituximab, dexamethasone) and 1 patient received lenalidomide as salvage therapy and six of them achieved complete remission. Three patients underwent allogeneic hematopoietic stem cell transplantation as well as two patients received ibrutinib as fourth line therapy and followed in remission. The 3 year overall survival was 71%.

Conclusion
ASCT is a part of initial treatment strategy in fit patients with mantle cell lymphoma however %19 patients in our series had transplant related toxicity. Today, novel agents may present a less intensive approach for achieving response.

Session topic: 22. Stem cell transplantation - Clinical

Keyword(s): Mantle cell lymphoma

Premium Sponsors

What's new at EHA

Browse the open-source material from EHA past Congresses and meetings.

References

EHA Terms & Conditions
2025 ©
European Hematology Association
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies